Company intelligence / Profile preview

StimuSIL

Ownership: Private
Development stage: Other

Overview

StimuSIL’s lead program SAGA-001 is a novel medical device that combines microneedling with precision low-level laser therapy for the treatment of androgenetic alopecia. The technology aims to deliver photobiomodulation energy directly into the dermal layer, bypassing melanin-related losses seen with conventional devices. A 24-week clinical trial was completed in Turkey in September 2024 to assess safety and efficacy for male pattern hair loss; results are pending publication. No FDA approval yet.

Therapeutic areas: Dermatology
Modalities: DeviceMicroneedling deviceLaser-based therapy (Photobiomodulation)Precision low-level laser therapy (LLLT)
Industry: Therapeutic Medical Devices

Partnerships

None publicly disclosed as of June 2025

Beyond the preview

Go deeper on StimuSIL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StimuSIL.

Explore the full profile